Stock Taper 
LKFT
$28.88
▼ DOWN 1.90% (-0.56)
KEY STATISTICS
Market Cap$1.90 B
52w High$37.78
52w Low$25.68
Dividend Yield—
Frequency—
P/E2.71
Volume143.74K
Shares Out.65.90M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Henry O. Gosebruch
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 5, 2005
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
452
PRICE TARGET
Target High$26.00
Target Low$26.00
Target Median$26.00
Target Consensus$26.00
UPCOMING EARNINGS
DateNov 12, 2026
DayThursday
Rev. Est.$8.95M
NOV
12
THU
PRICE
$28.88 ▼ DOWN 1.90% (−$0.56)About Lakefront Biotherapeutics N.V.
https://lakefrontbio.com ↗Galapagos NV, a Belgian biotech firm founded in 1999, develops small molecule and antibody therapies, including filgotinib and treatments for pulmonary fibrosis, with a pipeline spanning multiple clinical programs.
INDUSTRY
Biotechnology
A SERVICE LAKEFRONT BIOTHERAPEUTICS N.V. IS KNOWN FOR
Pharmaceutical Research and Development in Immunology and Oncology
Galapagos N.V. is a biotech company shifting focus to R&D in immunology and oncology, with a pipeline highlighted by a Gilead collaboration on T cell engager programs after divesting Jyseleca® and winding down cell therapy efforts.
RATINGS SNAPSHOT
Overall rating: A
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings3
Price To Book5
Overall Score4
MOST RECENT ANALYST GRADES
GRADE SUMMARY
EQUAL WEIGHT 1
SECTOR PERFORM 1
2 GRADES IN THE LAST 12 MONTHS
